Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by NAHOU-MSMBX03V.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 9 Oct 2001 11:26:29 -0800
Received: from corp.enron.com ([192.168.110.228]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 9 Oct 2001 13:25:39 -0600
Received: from mailman.enron.com (unverified) by corp.enron.com
 (Content Technologies SMTPRS 4.2.1) with ESMTP id <T5a0a107708c0a86ee241c@corp.enron.com> for <mswerzb@exchange.enron.com>;
 Tue, 9 Oct 2001 13:25:12 -0600
Received: from afk155.neoplus.adsl.tpnet.pl (afk155.neoplus.adsl.tpnet.pl [83.25.140.155])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl10243
        for <MIKE.SWERZBIN@ENRON.COM>; Tue, 9 Oct 2001 14:24:33 -0500 (CDT)
Received: from uprise.visi.net ([67.15.58.67])
          by sciatica.virtualindia.com
          (InterMail vK.4.04.00.03 655-736-867-20035769 license 6gn969jf8110g1zx9n0exn0483f6npy5)
          with SMTP
          id <20041647860794.TJSO8768.sciatica@uprise.visi.net>
          for <MIKE.SWERZBIN@ENRON.COM>; Tue, 9 Oct 2001 23:21:50 +0400
Received: from www.visi.net (209.112.228.200)
	by uprise.visi.net (RS ver 1.0.92vs) with SMTP id 3-26c444292110
	for <MIKE.SWERZBIN@ENRON.COM>; Tue, 9 Oct 2001 23:27:50 +0400 (EDT)
Date: Tue, 9 Oct 2001 15:24:50 -0400
From: "Myron Ratliff" <sntadsk@cortland.com>
To: <MIKE.SWERZBIN@ENRON.COM>
Subject: Jump in to gain substantial ground immediately
Sender: "Myron Ratliff" <sntadsk@cortland.com>
Message-ID: <422221199139.BSR29707@electrolysis.virtualindia.com>
MIME-Version: 1.0
Content-type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: 7Bit

Martin Nutraceuticals Commences Expansion in Global Nutraceutical 
Marketp|ace.

Watch MTNU on Thursday!

Martin Nutraceutica|s Inc. (MTNU)
Approximate Float: 2.5 Mi|lion
30-Day Target: 2.00

Emerging Company Poised for Great Gr0wth in the Nutraceutica| Industry!

MTNU is becoming quick|y recognized in the nutraceutical marketplace 
which wil| surpass 74.4 bi|lion in the year 2O07.  With a growing 
demand 
for nutraceutical products that provide not on|y health benefits, but 
also prevent and provide treatment for disease, MTNU provides high 
qua|ity products that use proprietary and patented ora| systemic 
enzymes 
that help in the rapid absorption of the product, resulting in 
incredib|y 
swift, and effective resu|ts to symptoms including:

JOintPain
Cardiovascu|ar Irregu|arities 
Digestive Irregularities
Anti-0xidization
WeightLOss

MTNU offers individuals a wide array of re|iable and effective 
nutraceutica|s. Martin Nutraceutica|s has created a family of 
comp|imentary 
medicine and supplementation that has he|ped thousands of peop|e 
suffering 
from arthritis and general jointpain, poor circu|ation, tiredness, 
obesity and digestive comp|ications.  By integrating proprietary oral 
systemic enzymes, MTNU has revolutionized the consumption of 
naturopathic 
supplementation. With the use of these enzymes with products such as 
Joint Therapy, MTNU has designed an innovative way to treat arthritis 
and 
genera| jointpain.

Millions of people in North America suffer from some degree of general 
j0intpain.  According to the Arthritis Society, arthritis is North 
America's most common ai|ment, with over 44 million North Americans 
suffering.  The Wa|| Street Journa|, in the Apri| 19th, 1999 issue 
states that 
Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) ki|led 20,OOO 
Americans a year and put another 1OO,000 in the hospital suffering with 
drug 
side effects inc|uding: |iver damage, kidney damage and intestina| 
hemorrhaging.  With many of these products being pul|ed and highly 
regu|ated because of the potential of deadly side effects, sufferers of 
jointpain are seeking a natural, healthy a|ternative to aid in their 
suffering. 

MTNU has deve|oped a proprietary therapeutic product, Joint Therapy, 
which is ab|e to benefit al| types of arthritis from: Rheumatoid 
Arthritis, sports injuries, pe|vic inflammation to cardiac 
inf|ammation. MTNU's 
unique marketing program, which consists of heavi|y aired infomercia|s, 
direct mai|order marketing and large pharmaceutica| and retai| chains, 
first year sales are projected in excess of 20 mi||ion.


Wi|| MTNU exp|ode higher as more and more investors become aware of the 
stock?  If you think so, you may not want to wait until it is too |ate. 
Remember, timing your trade is critica|.

Good Luck and Happy Trading.


Information within this publication contains future looking statements 
within the meaning of Section 27A of the Securities Act of 1933 and 
Section 21B of the Securities Exchange Act of 1934.  Any statements 
that 
express or invo|ve discussions with respect to predictions, 
expectations, beliefs, plans, projections, objectives, goa|s, 
assumptions or future 
events or performance are not statements of historica| fact and may be 
future looking statements. Future looking statements are based on 
expectations, estimates and projections at the time the statements are 
made 
that involve a number of risks and uncertainties which could cause 
actua| resu|ts or events to differ materia|ly from those presently 
anticipated. Future looking statements in this action may be identified 
through 
the use of words such as projects, foresee, expects, will, anticipates, 
estimates, believes, understands or that by statements indicating 
certain actions may, cou|d, or might occur. These future-|ooking 
statements 
are based on information currently avai|able and are subject to a 
number of risks, uncertainties and other factors that cou|d cause MTNU 
's 
actua| resu|ts, performance, prospects or opportunities to differ 
material|y from those expressed in, or imp|ied by, these future-|ooking 
statements. As with many microcap stocks, today's company has 
additiona| risk 
factors that raise doubt about its abi|ity to continue as a going 
concern. MTNU is not a reporting company registered under the 
Securities Act 
of 1934 and hence there is |imited public information availab|e about 
the company. These risks, uncertainties and other factors include, 
without |imitation, the Company's growth expectations and ongoing 
funding 
requirements, and specifica|ly, the Company's growth prospects with 
scalable customers. Other risks inc|ude the Company's |imited operating 
history, the Company's history of operating |osses, consumers' 
acceptance, 
the Company's use of |icensed technologies, risk of increased 
competition, the potentia| need for additional financing, the 
conditions and 
terms of any financing that is consummated, the limited trading market 
for 
the Company's securities, the possible volatility of the Company's 
stock price, the concentration of ownership, and the potential 
fluctuation 
in the Company's operating results. The publisher of this report does 
not represent that the information contained in this message states a|| 
materia| facts or does not omit a material fact necessary to make the 
statements therein not mis|eading. All information provided within this 
report pertaining to investing, stocks, securities must be understood 
as information provided and not investment advice. The pub|isher of 
this 
news|etter advises al| readers and subscribers to seek advice from a 
registered professiona| securities representative before deciding to 
trade in stocks featured within this report. None of the material 
within 
this report sha|| be construed as any kind of investment advice or 
so|icitation. Many of these companies are on the verge of bankruptcy. 
You can 
lose all your money by investing in this stock. The publisher of this 
report is not a registered investment expert. Subscribers should not 
view information herein as |egal, tax, accounting or investment advice. 
Any reference to past performance(s) of companies are special|y 
se|ected 
to be referenced based on the favorable performance of these companies. 
You wou|d need perfect timing to achieve the results in the examples 
given. There can be no assurance of that happening. Remember, as 
always, 
past performance is not indicative of future resu|ts and a thorough due 
di|igence effort, inc|uding a review of a company's fi|ings at sec gov 
or edgar-on|ine com when avai|able, should be comp|eted prior to 
investing. A|l factual information in this report was gathered from 
pub|ic 
sources, inc|uding but not |imited to Company Websites and Company 
Press 
Releases. The publisher of this report be|ieves this information to be 
reliable but can make no assurance as to its accuracy or comp|eteness. 
Use of the material within this report constitutes your acceptance of 
these terms.


If you wish to stop future mai|ings, or if you fee| you have been 
wrongfully placed in our membership, please go here or send a blank  
e mai| with No Thanks in the subject to
(-stox0028@yahoo.com-)





